Sign In  |  Register  |  About Walnut Creek Guide  |  Contact Us

Walnut Creek, CA
September 01, 2020 1:43pm
7-Day Forecast | Traffic

  • Search Hotels in Walnut Creek Guide

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Merck & Co (NY: MRK )

99.18 -0.68 (-0.68%)
Official Closing Price Updated: 7:00 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Merck & Co

< Previous 1 2
...
18 19 20 21 22 23 24 25 26
...
95 96 Next >
Merck Announces Phase 3 Trial Initiations for Four Investigational Candidates From its Promising Hematology and Oncology Pipeline
From Merck & Co., Inc.
Via Business Wire
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Stocks Edge Higher, Nasdaq Looks To Snap Skid
Stocks are attempting to regain their 2023 form today. 
Via Talk Markets
McDonald's Revenues Expected To Increase, Plus Merck And More On CNBC's 'Final Trades'
On CNBC’s "Halftime Report Final Trades," Joseph Terranova of Virtus Investment Partners named Merck & Co., Inc. (NYSE: MRK) 
Via Benzinga
What the Options Market Tells Us About Merck & Co
Via Benzinga
Looking Into Merck & Co's Recent Short Interest
Via Benzinga
2024 And Beyond – Exploring Six Investment Megatrends With Tema ETFs
A recent report from Tema ETFs, a leader in active exchange-traded funds (ETFs), offers a window into six emerging long-term megatrends. Its analysis provides a detailed account of evolving sectors,... 
Via Benzinga
Topics ETFs
AMD To Rally Over 25%? Here Are 10 Top Analyst Forecasts For Thursday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. 
Via Benzinga
Revenge of the Boring Stocks! Dividends Are Sexy Again.
Dividend stocks are leading the way in the first few days of 2024, indicating that boring is back! What that means for investors now. 
Via InvestorPlace
Tech Sell-Off Triggers Market Reset: Value Stocks Reach 7-Month High Versus Growth
U.S. stock market suffered worst start in two decades, tech sell-off led to cautious investor shift to value stocks, notably IUSV & IUSG ETFs + top gainers MRNA, VTRS, TNL, LVS & VAC. 
Via Benzinga
Topics ETFs
Merck to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
From Merck & Co., Inc.
Via Business Wire
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
There Are Only 5 Dow Stocks I Wouldn't Buy in 2024
There's a lot to like about Apple, Microsoft, and most of the Dow Jones Industrial Average components in 2024. 
Via The Motley Fool
Topics Stocks
Exposures US Equities
Moderna Stock Is Climbing Thanks to Merck, But Is It Still a Buy?
The pair's collaboration is making waves, and there's more to come. 
Via The Motley Fool
Upward Trajectory For Biotech/Pharma M&A: Sector Trends Towards Pre-Pandemic Levels, Forecasts Positive For 2024
According to the Global Data report, the pharma sector in Q3 2023 witnessed deals worth $28 billion, down 28% from the $54 billion recorded in Q2 2023.  
Via Benzinga
Common Investing Mistake: Income Obsession (& More)
A common investing mistake is income obsession. Others are holding too many stocks and focusing on valuation to know if the price of a stock is right. Sounds familiar? Any of these mistakes hurts your... 
Via Talk Markets
Pharmaceutical Giants Brace for Showdown as Medicare Drug Price Negotiations Are Poised For 2024
2024 will mark a pivotal moment for the healthcare industry, particularly in drug pricing negotiations. 
Via Benzinga
January Effect: 3 Under-the-Radar Stocks Poised for a New Year Jump
Are you looking to profit from the January effect? Here are three under-the-radar stocks poised for a new year's jump. 
Via InvestorPlace
MarketBeat Week in Review – 12/18 - 12/22
The torrid stock market rally cooled down a little bit heading into the extended holiday weekend; we wish you a Happy Holiday season with friends and family 
Via MarketBeat
Topics Economy
Exposures Interest Rates
7 Small-Cap Stocks That Wall Street Loves for Good Reason
The market rally is showing signs of broadening to include small-cap stocks, here are seven that analysts are upgrading 
Via InvestorPlace
Patritumab Deruxtecan Granted Priority Review in the U.S. for Certain Patients with Previously Treated Locally Advanced or Metastatic EGFR-Mutated Non-Small Cell Lung Cancer
From Daiichi Sankyo
Via Business Wire
7 Best Dow Jones Stocks to Buy for Conservative Investors
With many vagaries still surrounding the market, the best Dow Jones stocks for conservative investors offers a safer approach. 
Via InvestorPlace
Topics Stocks
Exposures US Equities
Merck's Chronic Cough Treatment Candidate Receives Second Time FDA Rejection
The FDA issued a Complete Response Letter (CRL) regarding Merck & Co Inc's (NYSE: MRK) New Drug Application (NDA) for gefapixant under development for the treatment of refractory chronic cough (RCC) or... 
Via Benzinga
Exposures Product Safety
Merck Provides U.S. Regulatory Update on Gefapixant
From Merck & Co., Inc.
Via Business Wire
Merck to Participate in the Goldman Sachs Healthcare C-Suite Unscripted Conference
From Merck & Co., Inc.
Via Business Wire
Better Dividend Stock: Bristol Myers Squibb or Merck?
These two pharma stocks have sizable dividend yields. Which is the better buy right now? 
Via The Motley Fool
FDA Grants Priority Review to Merck’s New Biologics License Application for V116, an Investigational, 21-valent Pneumococcal Conjugate Vaccine Specifically Designed to Protect Adults
From Merck & Co., Inc.
Via Business Wire
Jim Cramer Slams FTC Chair Lina Khan's Policies For Hampering Investor Returns: 'One-Woman Wrecking Crew For Your Stock Portfolio'
He posits that such actions have negatively impacted stock valuations. 
Via Benzinga
C4 Therapeutics blasts off: what's next?
As the market soars to new heights, C4 Therapeutics (NASDAQ: CCCC) has become the latest small-cap stock to explode higher in price and volume. 
Via MarketBeat
Topics ETFs
European Commission Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy for New First-Line Indications in Advanced HER2-Negative Gastric or GEJ Adenocarcinoma in Tumors Expressing PD-L1 (CPS ≥1) and Advanced Biliary Tract Cancer
From Merck & Co., Inc.
Via Business Wire
< Previous 1 2
...
18 19 20 21 22 23 24 25 26
...
95 96 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 WalnutCreekGuide.com & California Media Partners, LLC. All rights reserved.